Тreatment of uterine cervical dysplasia on the background of hyper proliferative disease of the corpus uteri in women of reproductive age

Authors

  • В. К. Кондратюк SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Ukraine https://orcid.org/0000-0001-6220-2116
  • Н. Є. Горбань SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Ukraine
  • Н. П. Дзісь Vinnitsa National Medical University named after M.I. Pirogov, Ukraine
  • А. І. Нарольська SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2017.37.52-57

Keywords:

cervical epithelial dysplasia, hyper proliferative diseases of the uterus body, human papillomavirus, reproductive age, treatment

Abstract

The work is devoted to increasing the effectiveness of treatment the dysplastic lesions of the cervical epithelium (DLCE) on the background of hyper proliferative diseases of the uterine body (HDUB) in women of reproductive age by developing a complex of diagnostic and therapeutic measures based on the study of clinical, cytological, colposcopy, microbiological, virological, morphological and immune histochemical features of the cervical epithelium.

The results of treatment of 90 women of reproductive age with DLCE on the background of HDUB were analyzed. Criteria for inclusion of patients in the study: CIN I, CIN II, CIN III, uterine leiomyoma, endometriosis of the uterus, papillomaviruses. Women of the main group (45 patients) received the developed diagnostic and treatment complex. The comparison group consisted of 45 patients, whose treatment was performed in accordance with regulatory documents.

Subject to confirmation of the inflammatory process of the pelvic organs, the participants of the study performed complex anti-inflammatory therapy (antibacterial, antiviral) taking into account the antibioticogram on the background of the immunomodulator, as well as antifungal, desensitizing, hepatoprotective and enzyme therapy. In particular, the immunomodulator tilorone and local anti-inflammatory treatment were used. Four weeks after the end of the conservative treatment, the elimination of pathogens and normalization of the microbiocenosis in 77.8% of the patients of the main group and in 64.4% of the women of the comparison group was confirmed.

In 33.3% of the women of the main group and 31.1% patients of the comparison group radio wave conization of the cervix was performed. For the prevention and treatment of intra- and postoperative bleedings during the surgical treatment of DLCE an anti-fibrinolytic drug was used. To improve the regenerative properties and prevent recurrence of DLCE in the postoperative period rehabilitative treatment with vaginal suppositories containing 100 mg of dexpanthenol and 16 mg of chlorhexidine bigluconate was used.

As the authors of the study noted, the use of complex of diagnostic and therapeutic measures in women of reproductive age with DLCE on the background of HDUB contributed to increase of the effectiveness of DLCE surgical treatment in 1.2 times, which allowed to safely use hormonal treatment of hyper proliferative pathology of the uterus body.

Author Biographies

В. К. Кондратюк, SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

MD, chief researcher at the Department of Family Planning 

Н. Є. Горбань, SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

PhD, senior researcher at the Department of Family Planning 

Н. П. Дзісь, Vinnitsa National Medical University named after M.I. Pirogov

MD, professor at the Obstetrics and Gynecology Department No. 2 

А. І. Нарольська, SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

Postgraduate student at the Department of Family Planning 

References

  1. Podolsky, V.V., Vovk, I.B., Kornatska, A.G. “Actual problems of reproductive health of women in Ukraine. ” Womеn’s Health 4 (2010): 121–6.
  2. Zhylka, N.Y., Zaikova, T.V. “Epidemiology of cervical cancer in Ukraine.” Ukraine. The health of nation 4 (2012): 40–7.
  3. Goida, N.G., Moiseenko, R.O., Maistruk, G.P. “The main achievements of the implementation of the State Program «Reproductive Health of the Nation» for 2005-2015.” Women’s Health 4 (2016): 14–6.
  4. Vorobiova, L.I., Zhylka, N.Y., Zaikova, T.V. “Problems of cervical pathology in Ukraine: analytical review of scientific literature.” Bulletin of social hygiene and health care administration of Ukraine 2 (2012): P. 14–6.
  5. Tsikouras, P., Zervoudis, S., Manav, B. “Cervical cancer: screening, diagnosis and staging.” J BUON 21.2 (2016): 320–5.
  6. Sha, Sh., Sidorova, I.S., Unanian, A.L., et al. “Clinico-anamnestic characteristics of patients with benign and precancerous cervix processes with combined pathology of the uterus.” Obstetrics, gynecology and reproduction 6.1 (2012): 23–6.
  7. Vdovichenko, Y.P., Golyanovskyi, O.V., Lopushan, O.I. “Uterine leiomyoma (Part 1).” The art of treatment 2–3 (2012): 47–52.
  8. Tatarchuk, T.F., Kalugina, L.V. “On the issue of the prevention and therapy of hormone-dependent hyperproliferative diseases in women.” Women’s Health 7 (2013): 51–7.
  9. Kondratiuk, V.K., Nikitina, I.M., Kondratiuk, K.O., Dziuba, G.A. “Hyperproliferative syndrome in gynecology and obesity.” Reproductive endocrinology 6 (2016): 59–62.
  10. Rogovskaya, S.I. “Complex therapy of the cervix with the use of drugs depantol and lavomax.” Obstetrics and Gynecology 10 (2014): 95–100.
  11. Kornatska, A.G., Borysiuk, O.Y., Gorban, N.E. “Clinical application of the drug Lavomax in the complex therapy of women with chronic inflammatory diseases of the pelvic organs of herpesvirus-bacterial etiology.” Womеn’s Health 4 (2008): 178–84.
  12. Kondratiuk, V.K., Yemets, N.O., Koblosh, N.D., Pustovalova, O.I. “Clinical application of the drug Lavomax in the treatment of inflammatory diseases of the cervix associated with the HPV.” Women’s Health 7.53 (2010): 206–10.
  13. Beniuk, V.O., Lastovetska, L.D., Shcherba, O.A. “Correction of vaginal biotope in women of reproductive age with genital herpes.” Reproductive endocrinology 2.22 (2015): 40–6.
  14. Bondarenko, G.M., Nikitenko, N.M., Shcherbakova, Y.G. “Optimization of therapy for the prevention of vulvovaginal candidiasis.” Reproductive endocrinology 6.20 (2014): 50–5.
  15. Chechuga, S.B. “Experience of application of tranexamic acid in obstetric and gynecological practice.” Women’s Health 1.97 (2015): 96–120.

Downloads

Published

2017-10-30

How to Cite

Кондратюк, В. К., Горбань, Н. Є., Дзісь, Н. П., & Нарольська, А. І. (2017). Тreatment of uterine cervical dysplasia on the background of hyper proliferative disease of the corpus uteri in women of reproductive age. REPRODUCTIVE ENDOCRINOLOGY, (37), 52–57. https://doi.org/10.18370/2309-4117.2017.37.52-57

Issue

No. 37 (2017)

Section

Gynecology

License

Copyright (c) 2017 В. К. Кондратюк, Н. Є. Горбань, Н. П. Дзісь, А. І. Нарольська

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.